Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Jan 12, 2021
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ziopharm Oncology Inc
| -18.02K |
$3.09 | -$55,681.80 | -21.98% | 63.97K | +1 |
Jan 8
|
Scheduled
| |||||
Ziopharm Oncology Inc
| 18K |
—
|
—
| +28.13% | 81.98K | +1 |
Jan 29
| ||||||
Ziopharm Oncology Inc
| -21.57K |
$4.55 | -$98,143.50 | -25.21% | 63.98K | +1 |
Dec 31 - Jan 2
|
Scheduled
| |||||
Ziopharm Oncology Inc
|
0
|
$4.05 | -$28,000.80 |
—
| 85.56K | +1 |
Nov 26
|
Scheduled
| |||||
Ziopharm Oncology Inc
| 37.12K |
—
|
—
| +76.65% | 85.56K | +1 |
Jan 6
| ||||||
Ziopharm Oncology Inc
| -40.10K |
$1.71 | -$68,527.80 | -45.29% | 48.43K | +1 |
Dec 29 - Dec 31
| ||||||
Ziopharm Oncology Inc
| 30.57K |
$4.14 | -$92,872.62 | +52.73% | 88.53K | +1 |
Dec 29 - Dec 31
| ||||||
Ziopharm Oncology Inc
| 29.97K |
$5.35 | -$49,931.55 | +107.02% | 57.97K | +1 |
Dec 30 - Dec 31
| ||||||
Ziopharm Oncology Inc
| 28K |
—
|
—
|
∞
| 28K | +1 |
Dec 31
| ||||||
Ziopharm Oncology Inc
| -26.67K |
$5.90 | -$489,166.20 | -100.00% |
0
| +2 |
Jun 3
| ||||||
Ziopharm Oncology Inc
| -4.69K |
$5.03 | -$23,590.70 | -14.96% | 26.67K | +2 |
Dec 30 - Dec 31
| ||||||
Ziopharm Oncology Inc
| -4.69K |
$4.34 | -$20,354.60 | -13.01% | 31.36K | +2 |
Dec 31
| ||||||
Ziopharm Oncology Inc
|
0
|
—
|
—
|
—
|
0
| +2 |
Jun 27
| ||||||
Ziopharm Oncology Inc
|
0
|
—
|
—
|
—
|
0
| +2 | |||||||
Helicos Biosciences Corp
|
0
|
—
|
—
|
—
|
0
| ||||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. | |||||||||||||